Corcept Therapeutics Incorporated (CORT) reported second-quarter 2024 earnings of 32 cents per share, which beat the Zacks Consensus Estimate of 23 cents. The company had reported earnings of 25 cents per share in the year-ago quarter. Quarter in Detail Research and development expenses surged 35.5% year over year to $58.7 million. Consequently, operating expenses increased to $128.2 million, up 45.5% from the year-ago quarter's level, owing to higher expenses related to ongoing clinical studies and support ...

Corcept Therapeutics Incorporated (NASDAQ:CORT) Q2 2024 Earnings Conference Call July 29, 2024 5:00 PM ET Company Participants Atabak Mokari - Chief Financial Officer Charles Robb - Chief Business Officer Joseph Belanoff - Chief Executive Officer, President and Director Sean Maduck - President of Endocrinology William Guyer - Chief Development Officer Conference Call Participants Matt Kaplan - Ladenburg Thalmann & Co. David Amsellem - Piper Sandler & Co. Swayampakula Ramakanth - H.C. Wainwright Joon Lee - T ...

This quarterly report represents an earnings surprise of 39.13%. A quarter ago, it was expected that this drug developer would post earnings of $0.21 per share when it actually produced earnings of $0.25, delivering a surprise of 19.05%. Corcept, which belongs to the Zacks Medical - Drugs industry, posted revenues of $163.8 million for the quarter ended June 2024, surpassing the Zacks Consensus Estimate by 6.41%. This compares to year-ago revenues of $117.72 million. The company has topped consensus revenue ...

There have been no material changes in our obligations under contractual agreements described in our Annual Report on Form 10-K for the year ended December 31, 2023. Melucci Litigation and Settlement On April 12, 2024, we entered into a six-year sublease (the "Sublease") with Zuora, Inc. for office space located at 101 Redwood Shores Parkway, Redwood City, California, effective from July 1, 2024. The leased property will serve as our new headquarters effective August 1, 2024. The portion of the premises sub ...

MENLO PARK, Calif., (July 29, 2024) – Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today reported its results for the quarter ended June 30, 2024. • Increase in 2024 revenue guidance to $640 – $670 million, from $620 – $650 million "Once again, we had a record number of new Korlym® prescribers ...

MENLO PARK, Calif., July 22, 2024 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT) today announced it will report second quarter financial results and provide a corporate update on July 29, 2024. The company will also host a conference call that day at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time). Conference Call Information Participants must register in advance of the conference call by clicking here. Upon registering, each participant will receive a dial-in number, and a unique acce ...

Shares of Corcept Therapeutics Incorporated (CORT) have rallied 20% in the past three months against the industry's decline of 4.9%. The GRACE study consists of two parts — the open-label portion and the randomized withdrawal phase. Last month, CORT announced that the GRACE study met the primary endpoint in the randomized withdrawal phase. Data from the same showed that patients who were treated with relacorilant experienced loss of blood pressure control, the study's primary endpoint, versus placebo. Notab ...

"Until now, hypercortisolism has been widely regarded as extremely rare. But that turns out not to be true. These results show that hypercortisolism among patients with difficult-to-control type 2 diabetes is much more common than previously assumed and is likely the underlying cause of diabetes in many cases," said Ralph DeFronzo, MD, chief of the Diabetes Division and professor of medicine at UT Health San Antonio and CATALYST study investigator. "These insights should lead to expanded screening for hyper ...

Results from the CATALYST clinical trial were presented at the American Diabetes Association's 84th Scientific Sessions at a featured plenary session titled: "Prevalence of Hypercortisolism in Difficult-toControl Type 2 Diabetes" With 1,055 patients enrolled, CATALYST is the largest and most rigorous study ever conducted to assess the prevalence of hypercortisolism in patients with difficult-to-control type 2 diabetes Results demonstrate a hypercortisolism prevalence rate of 24 percent in this patient popul ...

The Zacks Style Scores, developed alongside the Zacks Rank, are complementary indicators that rate stocks based on three widely-followed investing methodologies; they also help investors pick stocks with the best chances of beating the market over the next 30 days. Zacks Premium includes access to the Zacks Style Scores as well. Each stock is given an alphabetic rating of A, B, C, D or F based on their value, growth, and momentum qualities. With this system, an A is better than a B, a B is better than a C, ...